These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1486 related articles for article (PubMed ID: 16452206)

  • 1. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
    O'Reilly KE; Rojo F; She QB; Solit D; Mills GB; Smith D; Lane H; Hofmann F; Hicklin DJ; Ludwig DL; Baselga J; Rosen N
    Cancer Res; 2006 Feb; 66(3):1500-8. PubMed ID: 16452206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
    Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
    Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
    Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
    Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
    Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling.
    Martin KA; Merenick BL; Ding M; Fetalvero KM; Rzucidlo EM; Kozul CD; Brown DJ; Chiu HY; Shyu M; Drapeau BL; Wagner RJ; Powell RJ
    J Biol Chem; 2007 Dec; 282(49):36112-20. PubMed ID: 17908691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.
    Wan X; Harkavy B; Shen N; Grohar P; Helman LJ
    Oncogene; 2007 Mar; 26(13):1932-40. PubMed ID: 17001314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
    Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin is activated in association with myometrial proliferation during pregnancy.
    Jaffer S; Shynlova O; Lye S
    Endocrinology; 2009 Oct; 150(10):4672-80. PubMed ID: 19589861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.
    Tremblay F; Gagnon A; Veilleux A; Sorisky A; Marette A
    Endocrinology; 2005 Mar; 146(3):1328-37. PubMed ID: 15576463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
    Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
    Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation.
    Tzatsos A; Kandror KV
    Mol Cell Biol; 2006 Jan; 26(1):63-76. PubMed ID: 16354680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake.
    Ginion A; Auquier J; Benton CR; Mouton C; Vanoverschelde JL; Hue L; Horman S; Beauloye C; Bertrand L
    Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H469-77. PubMed ID: 21602475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.